The Thesis
Channel-pullback is a disciplined dip-buyer with a trend filter. It buys pullbacks to the lower regression channel or volume support only in confirmed uptrends, then exits into the upper channel or resistance. In other words, it tries to buy weakness without catching falling knives — the uptrend requirement is meant to keep it on the right side of momentum. It trades a 24-name large-cap universe spanning tech (AAPL, MSFT, NVDA), financials (JPM, V, MA), healthcare (JNJ, UNH), staples (KO, PG, COST) and energy (XOM, CVX).
Recent Activity
Live trading has been quiet. The scheduled runs from 2026-10-12 through 2026-10-19 executed at most one order per day — several days logged zero trades, zero rejections — leaving the paper account hovering around an $11,000 total value against roughly $9,058 in cash on the latest run. That low cash deployment is notable: the strategy is sitting on its hands, consistent with a model that simply isn't seeing qualifying pullbacks right now.
The prior fortnight was busier. It round-tripped PFE twice (buying 71 shares at $27.83 after selling at $28.08–$28.17) and XOM once (buying at $163.77, selling at $168.81 — a clean win into resistance). It also added NVDA at $220.45 and trimmed JNJ, KO, CVX and MA. The XOM and PFE exits illustrate the intended behaviour: take the pop into the upper channel.
Backtest Performance
Over 451 days the strategy returned 7.62% (final equity $10,761.52, CAGR 4.19%) with a Sharpe of just 0.40 and a 14.83% max drawdown. The win rate is a low 39.39% across 137 trades — meaning the average winner must substantially outrun the average loser for the equity curve to climb, which is typical and acceptable for this exit-into-strength style. Less comfortable is the 2,311% turnover: this strategy trades a lot, and while fees were modest here, that churn is a real-world cost and fragility risk.
Validation: It Failed
The walk-forward validation did not pass, and the reasons matter more than the headline return. Three of four folds were positive — Fold 3 was excellent (+20.68%, Sharpe 3.86) — but Fold 2 (Jan–Jul 2025) lost 11.42% with a Sharpe of −1.70 and a 16% drawdown. That single regime shows the strategy's Achilles' heel: when the "confirmed uptrend" filter whipsaws, pullback buys become trend-following into a decline.
The statistics confirm the caution. Out-of-sample return was 3.63% (OOS Sharpe 0.74) — roughly half the full-sample figure, a classic sign of mild overfitting. Most tellingly, with 7 trials the deflated Sharpe ratio was only 0.196 (PSR 0.702). That low DSR is why the gate held: the edge isn't robust enough to rule out selection luck.
Verdict
Channel-pullback is a coherent, sensibly-constructed strategy with a genuinely good fold and honest exits. But it is a marginal performer — low Sharpe, low win rate, high turnover, and one ugly regime — and the validation layer was right to flag it. It earns a watch, not a conviction allocation.